Sr. No.	Received from	Pending at the end of last month	Received	Resolved*	Total Pending #	Pending complaints >3months	Average Resolution time^ (in days)
1	Directly from Investors	0	0	0	0	0	0
2	SEBI (SCORES)	0	0	0	0	0	0
3	Other Sources (if any)	0	0	0	0	0	0
	Grand Total	0	0	0	0	0	0

Sr. No.	Month	Carried forward from previous month	Received	Resolved*	Pending#
1	Jun, 2026	0	0	0	0
2	Jul, 2026	0	0	0	0
3	Aug, 2026	0	0	0	0
	Grand Total	0	0	0	0

Sr. No.	Fin. Year	Received	Resolved*
1	2022-23	1	1
2	2023-24	0	0
3	2024-25	0	0
4	2025-26	1	1
	Grand Total	2	2

Alembic Group Stocks

1 Yr CAGR -15.03%

3 Yr CAGR -1.35%

Total Companies 3

List of Alembic Stocks as on 02-Nov-2026

Filter

	Company Name	DeciZen	CMP	Price Change	Market Cap (Cr)	52 Week High	52 Week Low	ROE	P/E Ratio	P / BV	EV/ EBITDA
1	Alembic Pharma	4 Q V+ PT	798	0.33%	15,682 Small Cap	998 04 Nov, 25	635 23 Mar, 26	12.64	22.61	2.68	13.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
2	Paushak	4 Q V PT	587	-5.42%	1,447 Small Cap	881 15 Oct, 26	343 30 Mar, 26	0.00	-	0.00	-	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
3	Alembic	4 Q V PT	87.20	-2.52%	2,239 Small Cap	118 03 Sep, 26	70.64 30 Mar, 26	13.14	6.98	0.91	13.89	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History

Top Business Houses

Tata

26 Companies

Market Cap: ₹ 25,76,034 Cr.

1 Yr CAGR -6.84%

3 Yr CAGR 2.07%

Mukesh Ambani

8 Companies

Market Cap: ₹ 17,27,645 Cr.

1 Yr CAGR -23.08%

3 Yr CAGR -5.44%

Adani

7 Companies

Market Cap: ₹ 15,96,901 Cr.

1 Yr CAGR 15.40%

3 Yr CAGR 11.47%

Bharti

3 Companies

Market Cap: ₹ 14,11,114 Cr.

1 Yr CAGR -6.84%

3 Yr CAGR 28.00%

Bajaj

12 Companies

Market Cap: ₹ 13,44,185 Cr.

1 Yr CAGR -12.30%

3 Yr CAGR 14.21%

HDFC

4 Companies

Market Cap: ₹ 13,22,410 Cr.

1 Yr CAGR -14.22%

3 Yr CAGR 2.35%

ICICI

4 Companies

Market Cap: ₹ 12,73,032 Cr.

1 Yr CAGR -5.82%

3 Yr CAGR 4.93%

PSU - SBI

4 Companies

Market Cap: ₹ 11,98,558 Cr.

1 Yr CAGR -17.55%

3 Yr CAGR 3.14%

News about Alembic Stocks in India

Oct, 2026

Alembic Pharmaceuticals gets USFDA’s final nod for Venetoclax Tablets

Alembic has a cumulative total of 248 ANDA approvals from the USFDA

Oct, 2026

Alembic Pharmaceuticals informs about press release

Alembic Pharmaceuticals has informed that it enclosed a e-copy of newspaper, containing the notice of loss of equity share certificate, published by the Company on behalf of the registered shareholder in English language newspaper - Business Standard on 28th October, 2026.

The above information is a part of company’s filings submitted to BSE.

Oct, 2026

Alembic Pharma shines on getting USFDA’s final nod for Valganciclovir for Oral Solution

Alembic has a cumulative total of 247 ANDA approvals from the USFDA

Oct, 2026

Alembic Pharma gets USFDA’s final nod for Valganciclovir for Oral Solution

Alembic has a cumulative total of 247 ANDA approvals from the USFDA

Oct, 2026

Alembic Pharmaceuticals informs about press release

Alembic Pharmaceuticals has informed that the Company has received US Food & Drug Administration (USFDA) Final Approval for Valganciclovir for Oral Solution, 50 mg/mL. A press release being issued in this regard is enclosed.

The above information is a part of company’s filings submitted to BSE.

Oct, 2026

Alembic Pharmaceuticals’ arm incorporates subsidiary in Dubai

The new entity aims to explore new business opportunities and to promote, sale and distribute pharmaceutical product(s) of the company

Track Now:

5 Star Companies Large Cap Companies Mid Cap Companies Small Cap Companies Nifty Microcap Companies Top IT Companies Tax saver funds Analyze your Equity Funds Nifty Index Funds

You have 4 views remaining as a Guest User. Login | Register Now

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Current Complaints

*Inclusive of complaints of previous months resolved in the current month. #Inclusive of complaints pending as on the last day of the month.

*Inclusive of complaints of previous months resolved in the current month. #Inclusive of complaints pending as on the last day of the year.

Alembic Group Stocks

Top Business Houses

Tata

Mukesh Ambani

Adani

Bharti

Bajaj

HDFC

ICICI

PSU - SBI

News about Alembic Stocks in India

Alembic Pharmaceuticals gets USFDA’s final nod for Venetoclax Tablets

Alembic Pharmaceuticals informs about press release

Alembic Pharma shines on getting USFDA’s final nod for Valganciclovir for Oral Solution

Alembic Pharma gets USFDA’s final nod for Valganciclovir for Oral Solution

Alembic Pharmaceuticals informs about press release

Alembic Pharmaceuticals’ arm incorporates subsidiary in Dubai

Track Now:

Trending Blogs